The clinical implementation of BRAF and MEK inhibitor therapies (including dabrafenib and trametinib and vemurafenib and cobimetinib) has resulted in dramatic improvements in OS and progression-free survival (PFS) rates in patients with BRAF-mutated advanced melanoma [19]. Here, MAP2K7 is linked to melanoma.